Skip to content

Belun Ring Validation Study for Assessment of Obstructive Sleep Apnea

A Validation Investigation of the Accuracy of the Belun Ring, an Innovative Single-channel Four-signal Pulse Oximetry, in Patients Referred to Sleep Lab for Assessment of Obstructive Sleep Apnea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03997916
Enrollment
113
Registered
2019-06-25
Start date
2019-05-06
Completion date
2019-07-30
Last updated
2023-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

Belun Ring, pulse oximeter, obstructive sleep apnea

Brief summary

This study aims to determine the overall accuracy, sensitivity, and specificity of the Belun Ring device in evaluating obstructive sleep apnea by comparing the device to the attended overnight in-lab polysomnography which is the gold standard for diagnosis of obstructive sleep apnea. Our hypothesis is that the Belun-Ring, a type 4 portable monitoring device, is overall sensitive and specific for evaluation of obstructive sleep apnea when compared to the attended overnight in-lab polysomnography.

Detailed description

This study will include all patients who are scheduled to do an attended overnight in-lab polysomnography in 2 sleep labs owned by University Hospitals Cleveland Medical Center. These patients will receive email recruitment forms 2 weeks prior their scheduled polysomnography. Whether they are interested or not, patients are supposed to call or email the study's central contact person. Both phone number and email address of the central contact person are noted in the email recruitment form. For those patients who did not make any contact with the study's central contact person, they will be screened for eligibility by sub-investigators through chart review. List of eligible patients will be sent to the central contact backup person who is basically in-charge of making phone calls to the patients. This person will further confirm patients' eligibility over the phone and ask if they are interested. If a patient is interested, the central contact backup person will inform the sub-investigators who, in turn, will assign a unique patient identifier to the interested subject and inform the sleep lab contact person. The sleep lab contact person will, in turn, inform the sleep technicians on-call ahead of time about the list of interested subjects. On the night of the polysomnography testing of the interested subject, the latter will receive questionnaires and written informed consent form related to the study which will be explained by the sleep technician. After the subject had completed and signed the questionnaires and written informed consent form respectively, the sleep technician will apply the Belun Ring device on the patient as well as the electrodes and sensors included in a routine polysomnography. The following day, data from Belun Ring device will be uploaded to the laptop while another sleep technician will read the polysomnography. Sub-investigators will enter the data from the questionnaires, Belun Ring device, and polysomnography in the secured University Hospitals Redcap (UHRedcap). Once the target number of subjects are reached, all data will be sent to statistician for analysis.

Interventions

All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.

DIAGNOSTIC_TESTPSG

All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.

Sponsors

Belun Technology Company Limited
CollaboratorOTHER
University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* All adult patients age 18-80 years old scheduled for overnight in-lab sleep study * Provision of signed and dated written informed consent form

Exclusion criteria

* Recent hospitalization in the past 30 days * Patients on home oxygen, non-invasive ventilator, diaphragmatic pacing, or any form of nerve stimulator * Patients with pacemaker, defibrillator, left ventricular assist device (LVAD), or status post cardiac transplantation * Patients with baseline heart rate under 50 bpm or over 100 bpm during last clinic visit or prior to study at the sleep lab * Patients with unstable cardiopulmonary status judged to be unsafe for sleep study by the sleep technician and/or the on-call sleep physician in the sleep lab on the night of the study * Patients who are unable to complete the required study * Patients involved in another investigational study * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Performance (Mean With 95% CI) of bAHI at PSG--AHI Cutoffs of 5, 15 and 30 (Accuracy)Same night when both testing were done on the same subjectComparing the accuracy, sensitivity, specificity of Belun Ring Device versus gold standard Polysomnography for Obstructive Sleep Apnea
SensitivitySame night when both testing were done on the same subjectComparing the accuracy, sensitivity, specificity of Belun Ring Device versus gold standard Polysomnography for Obstructive Sleep Apnea
SpecificitySame night when both testing were done on the same subjectComparing the accuracy, sensitivity, specificity of Belun Ring Device versus gold standard Polysomnography for Obstructive Sleep Apnea

Countries

United States

Participant flow

Pre-assignment details

Total of 336 subjects were screened, 130 subjects did not meet eligibility criteria. Out of the 206 subjects who were eligible, 93 refused to participate. Total of 113 subjects completed informed consent process and enrolled in the study.

Participants by arm

ArmCount
Participant
All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device. Belun Ring: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. PSG: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient.
78
Total78

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyProtocol Violation35

Baseline characteristics

CharacteristicParticipant
Age, Continuous51.5 years
STANDARD_DEVIATION 13.4
Body Mass Index (BMI)36.1 Kg/m^2
STANDARD_DEVIATION 10.1
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
30 Participants
Race (NIH/OMB)
Black or African American
41 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
White
4 Participants
Sex: Female, Male
Female
51 Participants
Sex: Female, Male
Male
27 Participants
STOP-Bang3.9 scores on a scale
STANDARD_DEVIATION 1.8

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 78
other
Total, other adverse events
0 / 78
serious
Total, serious adverse events
0 / 78

Outcome results

Primary

Performance (Mean With 95% CI) of bAHI at PSG--AHI Cutoffs of 5, 15 and 30 (Accuracy)

Comparing the accuracy, sensitivity, specificity of Belun Ring Device versus gold standard Polysomnography for Obstructive Sleep Apnea

Time frame: Same night when both testing were done on the same subject

ArmMeasureGroupValue (NUMBER)
Belun Ring Study ParticipantsPerformance (Mean With 95% CI) of bAHI at PSG--AHI Cutoffs of 5, 15 and 30 (Accuracy)AHI cut off of 50.564 proportion of events
Belun Ring Study ParticipantsPerformance (Mean With 95% CI) of bAHI at PSG--AHI Cutoffs of 5, 15 and 30 (Accuracy)AHI cut off of 150.808 proportion of events
Belun Ring Study ParticipantsPerformance (Mean With 95% CI) of bAHI at PSG--AHI Cutoffs of 5, 15 and 30 (Accuracy)AHI cut off of 300.910 proportion of events
Primary

Sensitivity

Comparing the accuracy, sensitivity, specificity of Belun Ring Device versus gold standard Polysomnography for Obstructive Sleep Apnea

Time frame: Same night when both testing were done on the same subject

ArmMeasureGroupValue (NUMBER)
Belun Ring Study ParticipantsSensitivityAHI cut off at 51.000 proportion of events
Belun Ring Study ParticipantsSensitivityAHI cut off at 150.931 proportion of events
Belun Ring Study ParticipantsSensitivityAHI cut off at 300.714 proportion of events
Primary

Specificity

Comparing the accuracy, sensitivity, specificity of Belun Ring Device versus gold standard Polysomnography for Obstructive Sleep Apnea

Time frame: Same night when both testing were done on the same subject

ArmMeasureGroupValue (NUMBER)
Belun Ring Study ParticipantsSpecificityAHI cut off of 50.029 proportion of events
Belun Ring Study ParticipantsSpecificityAHI cut off of 150.735 proportion of events
Belun Ring Study ParticipantsSpecificityAHI cut off of 300.953 proportion of events

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026